600572 Stock Overview
Engages in the research and development, manufacturing, and sales of medicines and general health products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Zhejiang CONBA Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.73 |
| 52 Week High | CN¥5.54 |
| 52 Week Low | CN¥3.91 |
| Beta | 0.41 |
| 1 Month Change | 3.05% |
| 3 Month Change | 11.29% |
| 1 Year Change | -4.44% |
| 3 Year Change | -0.84% |
| 5 Year Change | -23.09% |
| Change since IPO | 197.00% |
Recent News & Updates
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit
Nov 05
It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)
Sep 30Recent updates
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit
Nov 05It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)
Sep 30Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?
Sep 12Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?
Aug 20Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly
May 21Shareholder Returns
| 600572 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.0% | -1.0% | 0.4% |
| 1Y | -4.4% | -3.0% | 12.3% |
Return vs Industry: 600572 matched the CN Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: 600572 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 600572 volatility | |
|---|---|
| 600572 Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 600572 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600572's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 8,411 | Guoliang Luo | www.conbagroup.com |
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, manufacturing, and sales of medicines and general health products in China. It offers Chinese herbal decoction pieces, Chinese patent medicines, chemical pharmaceutical products, chemical raw materials, medical devices, and biological products.
Zhejiang CONBA Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600572 fundamental statistics | |
|---|---|
| Market cap | CN¥11.86b |
| Earnings (TTM) | CN¥486.79m |
| Revenue (TTM) | CN¥6.46b |
24.4x
P/E Ratio1.8x
P/S RatioIs 600572 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600572 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.46b |
| Cost of Revenue | CN¥3.09b |
| Gross Profit | CN¥3.37b |
| Other Expenses | CN¥2.88b |
| Earnings | CN¥486.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 52.14% |
| Net Profit Margin | 7.53% |
| Debt/Equity Ratio | 6.2% |
How did 600572 perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield104%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:59 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang CONBA Pharmaceutical Co.,Ltd. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |